Petlife Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTLF research report →
Companywww.petlifepharma.com
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors.
- CEO
- Sebastian Serrell-Watts
- IPO
- 2008
- Employees
- 1
- HQ
- Los Angeles, CA, US
Price Chart
Valuation
- Market Cap
- $19.68K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1007.59%
- ROIC
- 3410.55%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,256,850 · -530.77%
- EPS
- $-0.33 · 17.50%
- Op Income
- $-22,655,379
- FCF YoY
- -110.04%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.91
- Avg Volume
- 417
Get TickerSpark's AI analysis on PTLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PTLF Coverage
We haven't published any research on PTLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PTLF Report →